This Article Full Text (PDF) Other Versions of this Article: AAC.01110-06v1 50/12/4191    most recent Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via Google Scholar Google Scholar Articles by KOSOWSKA-SHICK, K. Articles by APPELBAUM, P. C. Search for Related Content PubMed PubMed Citation Articles by KOSOWSKA-SHICK, K. Articles by APPELBAUM, P. C.

 Previous Article  |  Next Article 

Antimicrob. Agents Chemother. doi:10.1128/AAC.01110-06
Copyright (c) 2006, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights Reserved.

ACTIVITY OF DX-619 COMPARED TO OTHER AGENTS AGAINST VIRIDANS STREPTOCOCCI, STREPTOCOCCUS BOVIS AND CARDIOBACTERIUM HOMINIS

Hershey Medical Center, Hershey, PA 17033 and JMI Laboratories, North Liberty, IA 52317

^* To whom correspondence should be addressed. Email: pappelbaum{at}psu.edu.

	Abstract

Against 198 viridans streptococci, 25 Streptococcus bovis and 5 Cardiobacterium hominis, MICs of DX-619, a des-F(6)-quinolone, were 0.004-0.25 µg/ml. MICs were lower than other quinolones (0.008->32 µg/ml). -lactam MICs were 0.008-16 µg/ml. Azithromycin resistance was found in most species, while most were telithromycin susceptible. Glycopeptides and linezolid were active against viridans strains but inactive against C.hominis.